# Commercialization of automated mobile device for accurate comprehensive refraction

> **NIH NIH R44** · PLENOPTIKA, INC. · 2022 · $717,387

## Abstract

Summary
The goal of this CRP SBIR application is to commercialize QuickSee Plus that was researched and
developed during SBIR Phase 2 work. QuickSee Plus, will be a unique tool for eye care professionals that
enables comprehensive refraction (objective and subjective) in a single, portable package. It will provide
tremendous value for eye care professionals as it improves their efficiency within the clinic and extends
their reach outside the clinic, thereby, greater accessibility to refractive eye care for health disparity
populations

## Key facts

- **NIH application ID:** 10359070
- **Project number:** 5R44EY025452-05
- **Recipient organization:** PLENOPTIKA, INC.
- **Principal Investigator:** Gary Yiu-Kin Chu
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $717,387
- **Award type:** 5
- **Project period:** 2015-09-30 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10359070

## Citation

> US National Institutes of Health, RePORTER application 10359070, Commercialization of automated mobile device for accurate comprehensive refraction (5R44EY025452-05). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10359070. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*